<DOC>
	<DOCNO>NCT01514721</DOCNO>
	<brief_summary>The purpose study assess efficacy tolerability change DuoTrav® ( Travoprost 0.004 % /Timolol 0.5 % BAK-free ) prior Xalacom® Ganfort® fix combination pharmacotherapy patient open-angle glaucoma ocular hypertension uncontrolled intraocular pressure ( IOP ) .</brief_summary>
	<brief_title>Efficacy Changing DuoTrav® ( Travoprost 0.004 % /Timolol 0.5 % BAK-Free Fixed Combination ) From Prior Therapy</brief_title>
	<detailed_description />
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Travoprost</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<criteria>Clinical diagnosis ocular hypertension , openangle glaucoma , pigment dispersion glaucoma eye . On stable IOPlowering regimen prostaglandin fix combination ( either Xalacom Ganfort ) within 4 week prior Screening Visit . IOP 19 35 mmHg time day least 1 eye . Best correct visual acuity ( BCVA ) 6/60 ( 20/200 Snellen ; 1.0 LogMAR ) good eye . Willing discontinue use ocular hypotensive medication ( ) prior receive study medication entire course study . Other protocoldefined inclusion criterion may apply . Known medical history allergy , hypersensitivity , poor tolerance component DuoTrav® deem clinically significant opinion Principal Investigator . Corneal dystrophies either eye . Risk visual field VA worsen consequence participation study , investigator 's best judgment . Any disease condition would preclude safe administration topical betablocker , present special risk subject , interfere optimal participation study . Women pregnant lactating . Participation investigational study within 30 day prior Screening Visit . Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Open-angle glaucoma</keyword>
	<keyword>Ocular hypertension</keyword>
	<keyword>Pigment dispersion glaucoma</keyword>
</DOC>